Interleukin‐10 overexpression in macrophages suppresses atherosclerosis in hyperlipidemic mice
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
In atherogenesis, macrophage foam cell formation is modulated by pathways involving both the uptake and efflux of cholesterol. We recently showed that interleukin‐10 (IL‐10) modulates lipid metabolism by enhancing both uptake and efflux of cholesterol in macrophages. However, the mechanistic details of these properties in vivo have been unclear. Thus, the purpose of this study was to determine whether expression of IL‐10 in macrophages would alter susceptibility to atherosclerosis and whether IL‐10 exerts its antiatherosclerotic properties by modulating lipid metabolism in macrophages. We utilized a macrophage‐specific retroviral vector that allows long‐term in vivo expression of IL‐10 in macrophages through transplantation of retrovirally transduced bone marrow cells (BMCs). IL‐10 expressed by macrophages derived from transduced BMCs inhibited atherosclerosis in LDLR −/− mice by reducing cholesteryl ester accumulation in atherosclerotic sites. Experiments with primary macrophages indicated that macrophage source of IL‐10 stimulated both the uptake (by up‐regulating scavenger receptors) and efflux of cholesterol (by activating the PPARγ‐LXR‐ABCA1/ABCG1 pathway), thereby reducing inflammation and apoptosis in atherosclerosis. These findings indicate that BMC‐transduced macrophage IL‐10 production can act as a strong antiatherogenic agent, and they highlight a novel antiatherosclerotic therapy using a simple, yet effective, stem cell transduction system that facilitates long‐term expression of IL‐10 in macrophages.—Han, X., Kitamoto, S., Wang, H., Boisvert, W. A. Interleukin‐10 overexpression in macrophages suppresses atherosclerosis in hyperlipidemic mice. FASEB J . 24, 2869–2880 (2010). www.fasebj.org
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interleukin-10 and the Interleukin-10 Receptor
Moore, K. W., de Waal Malefyt, R., Coffman, R. L., & O'Garra, A. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.683 · Cited by 6,737 · cited 3×
“Its principal roles are to inhibit macrophage activation (by inhibiting NF- B) and cell death, as well as to limit the production of matrix metalloproteinase (MMP) and proinflammatory cytokines (14).”
BackgroundInfluentialTangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1
Rust, S., Rosier, M., Funke, H., Real, J., Amoura, Z., Piette, J.-C., Deleuze, J.-F., Brewer, H. B., Duverger, N., Denèfle, P., et al. (1999) · Nature Genetics · doi:10.1038/11921 · Cited by 1,433
A PPARγ-LXR-ABCA1 Pathway in Macrophages Is Involved in Cholesterol Efflux and Atherogenesis
Chawla, A., Boisvert, W. A., Lee, C.-H., Laffitte, B. A., Barak, Y., Joseph, S. B., Liao, D., Nagy, L., Edwards, P. A., Curtiss, L. K., et al. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00164-2 · Cited by 1,347 · cited 13×
“The sequence-specified PCR primers for SR-I, SR-II, CD36, ABCA1, ABCG1, apoE, PPAR , LXR , LXR , MCP-1, TNF- , MMP-9, TIMP-1, and GAPDH are described below.”
BackgroundSelf-citationThe macrophage foam cell as a target for therapeutic intervention
Li, A. C., & Glass, C. K. (2002) · Nature Medicine · doi:10.1038/nm1102-1235 · Cited by 700
Scavenger Receptors in Atherosclerosis: Beyond Lipid Uptake
Moore, K. J., & Freeman, M. W. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000229218.97976.43 · Cited by 562
Increased Atherosclerosis in Hyperlipidemic Mice With Inactivation of ABCA1 in Macrophages
Aiello, R. J., Brees, D., Bourassa, P.-A., Royer, L., Lindsey, S., Coskran, T., Haghpassand, M., & Francone, O. L. (2002) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000014804.35824.da · Cited by 390 · cited 16×
“ABCA1 mediates the efflux of cellular cholesterol to extracellular acceptors such as lipid-poor apoA1 (9), whereas ABCG1 facilitates macrophage cholesterol efflux to HDL (10).”
BackgroundInfluentialLeukocyte ABCA1 controls susceptibility to atherosclerosis and macrophage recruitment into tissues
Van Eck, M., Bos, I. S. T., Kaminski, W. E., Orsó, E., Rothe, G., Twisk, J., Böttcher, A., Van Amersfoort, E. S., Christiansen-Weber, T. A., Fung-Leung, W.-P., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.092327399 · Cited by 348 · cited 1×
“The disruption of either ABCA1 (41) or ABCG1 (10) causes a massive lipid accumulation in macrophages and leads to more severe atherosclerosis (13, 41).”
BackgroundIncreased ABCA1 activity protects against atherosclerosis
Singaraja, R. R., Fievet, C., Castro, G., James, E. R., Hennuyer, N., Clee, S. M., Bissada, N., Choy, J. C., Fruchart, J.-C., McManus, B. M., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15748 · Cited by 250
Cited by
Macrophages in the Pathogenesis of Atherosclerosis
Moore, K. J., & Tabas, I. (2011) · Cell · doi:10.1016/j.cell.2011.04.005 · Cited by 2,669
Murphy, A. J., Akhtari, M., Tolani, S., Pagler, T., Bijl, N., Kuo, C.-L., Wang, M., Sanson, M., Abramowicz, S., Welch, C., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57559 · Cited by 521
Cytokines in atherosclerosis: Key players in all stages of disease and promising therapeutic targets
Ramji, D. P., & Davies, T. S. (2015) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2015.04.003 · Cited by 469
McLaren, J. E., Michael, D. R., Ashlin, T. G., & Ramji, D. P. (2011) · Progress in Lipid Research · doi:10.1016/j.plipres.2011.04.002 · Cited by 397
Inflammation in acute myocardial infarction: the good, the bad and the ugly
Matter, M. A., Paneni, F., Libby, P., Frantz, S., Stähli, B. E., Templin, C., Mengozzi, A., Wang, Y.-J., Kündig, T. M., Räber, L., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehad486 · Cited by 357
Metadata
- Authors
- Han, X., Kitamoto, S., Wang, H., & Boisvert, W. A.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2010-03-30
- Volume
- 24
- Issue
- 8
- Pages
- 2869-2880
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W1979151464
- Cited by
- 143
- References
- 8
- FWCI
- 9.94
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.